Jade Biosciences Released Preclinical Data for JADE301

The company revealed new antibody findings ahead of a planned 2026 Phase 1 clinical trial.

Updated on Sept. 30, 2026 in Biotech

Jade Biosciences Released Preclinical Data for JADE301

Live Poll

Would you prioritize new treatments that require less frequent administration for chronic health conditions?

Jade Biosciences has released preclinical data for JADE301, an anti-IFN-β antibody designed to treat dermatomyositis. The experimental treatment aims to address both skin and muscle symptoms while reducing the overall treatment burden for patients.

Why it matters

Dermatomyositis affects approximately 50,000 adults in the United States, and new therapies are needed to manage its complex manifestations. JADE301 uses a YTE modification to neutralize IFN-β and inhibit harmful signaling pathways.

JADE301 demonstrated a binding affinity of 11.3 pM and a 25-day half-life in non-human primate studies. Models predict human subcutaneous bioavailability between 73% and 75%, with drug concentrations in muscle tissue reaching 1% to 4% of serum levels.

The players

Jade Biosciences

This biotechnology company focuses on developing advanced antibody therapies for rare autoimmune diseases.

The details

Researchers evaluated the antibody through non-human primate toxicology studies, finding it well tolerated at doses up to 200 mg/kg. The treatment works by employing a YTE modification to effectively neutralize IFN-β within the body.

Jade Biosciences announced the preclinical data on September 30, 2026.
The company plans to start a Phase 1 clinical trial in the fourth quarter of 2026.
Interim data from the Phase 1 trial is expected in the second half of 2027.

The Tech Race

JADE301 represents the broader industry shift toward using YTE modification technology to enhance antibody durability and reduce patient dosing frequency. This approach positions Jade Biosciences to compete in the growing market for specialized autoimmune biologics.

Patients with dermatomyositis may eventually benefit from a treatment designed to simplify their care routine by targeting both skin and muscle symptoms simultaneously. The focus on subcutaneous administration aims to make potential future therapy more manageable than current options.

The takeaway

The progression of JADE301 into clinical testing represents a significant milestone for those managing dermatomyositis. Success in upcoming trials could provide a new pathway for patients seeking more effective and convenient management of this rare condition.

What happens next

Jade Biosciences expects to initiate a Phase 1 clinical trial in the fourth quarter of 2026, followed by the release of interim trial data in the second half of 2027.